Compositions and methods for treating neoplastic diseases
First Claim
Patent Images
1. A method of treating a neoplastic disease, comprising:
- administering to a patient inflicted with the neoplastic disease a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof;
wherein X is selected from the group consisting of fluorine, chlorine, bromine or iodine, and wherein the neoplastic disease is susceptible to resistance to at least one other chemotherapeutic agent.
4 Assignments
0 Petitions
Accused Products
Abstract
Disclosed herein are compositions and methods for treating neoplastic diseases. Included are compositions and methods that are effective against multiple myeloma cells resistant to conventional and bortezomib treatment. Furthermore, combination treatment with two different proteosome inhibitors is shown to be synergistic for treating multiple myeloma.
39 Citations
37 Claims
-
1. A method of treating a neoplastic disease, comprising:
-
administering to a patient inflicted with the neoplastic disease a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof;
wherein X is selected from the group consisting of fluorine, chlorine, bromine or iodine, and wherein the neoplastic disease is susceptible to resistance to at least one other chemotherapeutic agent. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
-
12. A method of treating a neoplastic disease, comprising administering to a patient inflicted with the neoplastic disease a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof:
-
wherein X is selected from the group consisting of fluorine, chlorine, bromine or iodine, in combination with at least one additional chemotherapeutic agent. - View Dependent Claims (13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)
-
-
15. The method of claim 12, wherein the neoplastic disease is cancer.
-
16. The method of claim 15, wherein the cancer is selected from the group consisting of breast cancer, sarcoma, leukemia, ovarian cancer, uretal cancer, bladder cancer, prostate cancer, colon cancer, rectal cancer, stomach cancer, lung cancer, lymphoma, multiple myeloma, pancreatic cancer, liver cancer, kidney cancer, endocrine cancer, skin cancer, melanoma, angioma, and brain or central nervous system (CNS) cancer.
-
17. The method of claim 16, wherein the cancer is selected from the group consisting of multiple myeloma, colorectal carcinoma, prostate carcinoma, breast adenocarcinoma, non-small cell lung carcinoma, and an ovarian carcinoma or melanoma.
-
18. The method of claim 17, wherein the cancer is a multiple myeloma.
-
19. The method of claim 12, wherein the patient is a human.
-
20. The method of claim 12, wherein the other chemotherapeutic agent is selected from the group consisting of dexamethasone, doxorubicin, and thalidomide.
-
21. The method of claim 12, wherein the other chemotherapeutic agent is a proteosome inhibitor.
-
22. The method of claim 21, wherein the other chemotherapeutic agent is bortezomib.
-
23. The method of claim 12, wherein the combination is synergistic.
-
24. The method of claim 12, wherein the combination is additive.
-
25. A pharmaceutical composition, comprising:
-
a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof;
wherein X is selected from the group consisting of fluorine, chlorine, bromine or iodine; and
at least one additional chemotherapeutic agent. - View Dependent Claims (26, 27, 28, 29, 30)
-
- 31. A method of treating a neoplastic disease, comprising administering to a patient inflicted with the neoplastic disease a synergistic combination of at least two proteosome inhibitors.
Specification